Table I.

First line setting and maintenance.

Study (year)	Treatment	Patients	End points (months)	HR (95% CI)	p value
Hurwitz et al. AVF2107 (2004)	IFL+placebo vs. IFL+Bevacizumab	813	OS (15.6 vs. 20.3)	0.66 (0.54–0.81)	< 0.001
		411 vs. 402	PFS (6.2 vs. 10.6)	054 (0.45–0.66)	< 0.001
Saltz et al NO16966 (2008)	CapOX or FOLFOX4 +/− Bevacizumab	1401 (1400)	PFS (8.0 vs. 9.4)	0.83 (0.72–0.95)	0.0023
		701 vs. 699	OS (19.9 vs. 21.3)	0.89 (0.76–1.03)	0.0769
Loupakis et al. TRIBE (2014)	FOLFIRI + Bevacizumab vs. FOLFOXIRI + Bevacizumab	508	PFS (9.7 vs. 12.1)	0.75 (0.62-0.90)	0.003
		256 vs. 252	OS (25.8 vs. 31.0)	0.79 (0.63–1.00)	0.054
Hegewisch et al AIO0207 (2015)	Fluoropyimidine+Bevacizumab vs. no treatment	837 (472)	TFS (6.9 vs. 61 vs. 64)	1.08 (0.85-1.37)	0.53
		158vs.156vs.158	OS (23.8 vs. 26.2 vs. 23.1)	0.99 (0.71–1.38)	0.7
Simkens et al. CAIRO3 (2015)	no maintenance vs. maintenance Capecitabine+Bevacizumab	558	PFS2 (10.5 vs. 11.8)	0.66 (0.54–0.79)	<0.0001
		279 vs. 279	PFS1 (4.1 vs. 8.5)	0.40 (0.33-0.48)	<0.0001